Showing 119 of 119on this page. Filters & sort apply to loaded results; URL updates for sharing.119 of 119 on this page
Investor Centre | Dimerix Limited
DIMERIX AND TAIBA ENTER INTO AN EXCLUSIVE LICENSE AGREEMENT TO ...
Dimerix posts positive Phase 2a in CKD - BioTuesdays
Dimerix Biosciences Pty Ltd - Crunchbase Company Profile & Funding
DMX-200 for Focal Segmental Glomerulosclerosis (FSGS) - Dimerix Limited
Amicus Therapeutics licenses DMX-200 from Dimerix for ~$590M ...
Dimerix Limited on LinkedIn: Dimerix Phase 3 Interim Analysis Webinar
Dimerix Limited on LinkedIn: Dimerix Investor Webinar - Exclusive ...
Dimerix at the Australian Microcap Investment Conference - YouTube
Dimerix is pleased to announce positive data in its Phase 2a trial in ...
Dimerix hits 70pc recruitment milestone in rare kidney disease drug ...
Dimerix on a tear as patients line up for Phase 3 testing of COVID-19 ...
Dimerix Limited on LinkedIn: Dimerix Investor Webinar
Dimerix | ACTION3 study FSGS | USA
Why Dimerix is sparking a major push into Asia-Pacific’s biotech boom ...
Dimerix talks Phase 3 clinical trial ahead of Peak Asset Management ...
Presentation: Dimerix - Ignite Investment Summit, Hong Kong, October ...
“Today, Dimerix proudly celebrates our 20th anniversary. As we look ...
What’s in store for 2024: Dimerix - Stockhead | Dimerix Limited
Dimerix targets ‘important new drug discovery’ in the treatment of ...
DMX 200 grows in promise for Dimerix
Long Shortz: Dimerix | The Australian
Dimerix launches first paediatric trial site in Mexico for DMX-200
Dimerix Limited (ASX:DXB) - Shares, Dividends & News - Intelligent Investor
Dimerix to launch diabetes-related disease trial in Australia; FDA ...
Dimerix Limited
ACTION3 Phase 3 Study - Dimerix Limited
Dimerix CEO says phase 3 trials means much higher chance of taking its ...
Dimerix (ASX:DXB) gets ready for game day
Dimerix raises $8.7 million to advance Phase 3 trial for kidney drug ...
Dimerix Reports Positive Data Supporting Action3 Study of DMX-200 to ...
Dimerix completes ‘highly strategic’ $20m cap raise to advance ACTION3 ...
Health Check: Dimerix shares soar as the company hooks the billion ...
Dimerix is a small Melbourne-based company driving multiple global ...
Dimerix ticks another box in its Action3 Phase-3 FSGS kidney trial ...
Dimerix opens first Japan kidney trial site | The Cairns Post
Dimerix banks US$30m in US licensing deal | The Australian
Biocurious: Dimerix could be riding big and beautiful kidney drug ...
Dimerix (ASX: DXB) up 154% - But it’s not a $230 million deal, it’s a ...
Dimerix soars on $230m licensing deal with ADVANZ PHARMA for DMX-200 ...
Dimerix Limited - AnnualReports.com
Dimerix releases CLARITY 2.0 results, confirms DMX-200 is safe for ...
Dimerix completes seventh IDMC review | The Australian
Dimerix Limited (ASX: DXB) share price, news & information - Small Caps
‘A key milestone’: Dimerix ACTION3 Phase 3 trial interim results meet ...
Dimerix to Begin Work on Treatment for Diabetic Kidney Disease
Dimerix first patient completes Phase 3 trial and enters into long-term ...
Dimerix Nears a Potential First-in-Class Approval in a High-Value ...
Welcome! You are invited to join a webinar: Dimerix Investor Webinar ...
Dimerix secures deal to commercialise DMX-200 for treatment of rare ...
Dimerix announces changes to investigator-led remap-cap Covid-19 study ...
Dimerix strikes mega Middle East deal on ausbiz
Pipeline - Dimerix Limited
Dimerix gains NMPA approval for IND, opening doors to global phase ...
Dimerix achieves successful second key review for its Phase 3 FSGS ...
Dimerix gains on China drug application approval - Stockhead
Break it Down: Dimerix inks major Japanese partnership - Stockhead
Dimerix hits key milestone in Europe with first regulatory approval for ...
Dimerix (ASX:DXB) Share Price News
Dimerix welcomes FDA approval of similar kidney disease drug, using ...
Dimerix shares up 25pc in July as FDA confirms Phase 3 study design for ...
Dimerix moves fast to patent DMX-700 after ‘important new drug ...
Dimerix Advances Kidney Disease Treatment with Positive PARASOL Data ...
Dimerix (DXB) is the STOCK of the DAY - YouTube
Dimerix awarded $2.8 million R&D tax incentive claim to advance ACTION3 ...
Dimerix Limited on LinkedIn: CEO & Managing Director Dr Nina Webster ...
2020 is just getting better for biotech Dimerix - Stockhead
Dimerix | ACTION3 study FSGS | Japan
Dimerix (ASX:DXB) completes data collection for first interim analysis ...
Dimerix banks $3.2m from Japanese deal | The Australian
Dimerix (ASX:DXB) to rapidly expand clinical trial after passing major ...
SUCCESSFUL A$20M PLACEMENT TO FUND DIMERIX PHASE 3 TRIALS
ASX Health Quarterly Wrap: Dimerix inks fourth licensing deal, Audeara ...
Q+A: Dimerix CEO on upcoming milestone Phase III interim trial results ...
Dimerix ends 2022 with Phase 3 trial for DMX-200 ACTION3 recruited and ...
About - Dimerix Limited
Dimerix receives key paediatric investigation approval in UK | Stockhead
Dimerix confirms delivery method for DMX-200 in COVID-19 treatment, as ...
Dimerix strikes $120m licensing deal for kidney drug in Middle East ...
Exclusive Insights: Shares In Value Interview with Dimerix Limited CEO ...
Dimerix says FDA confirms proteinuria as acceptable endpoint for DMX ...
Dimerix receives $10.7 million upfront payment from Advanz Pharma ...
Access to this site | Dimerix Limited
Dimerix launches $12 million cap raise to advance Phase 3 trial for ...
Dimerix leading race to find treatment for slowing progression of ...
Dimerix - DXB(ASX) News & Expert Insights from Stockhead
Break it Down: Dimerix inks major Japanese partnership - Stockhead ...
Break it Down: Dimerix inks major Japanese partnership
Dimerix Limited on LinkedIn: 063yfyfwy6b2wf.pdf
About Us | CCeMMP
Dimerix（ASX：DXB）公布PARASOL最终数据分析结果 支持FSGS关键终点设定并推进FDA审批沟通 - 澳洲财经新闻 | 澳洲 ...
Next Investors
FDA confirms primary goal for Dimerix’s DMX-200 trial for FSGS
The Best ASX Biotechnology Stocks - The Bull
Dimerix’s ACTION3 phase III fully recruited | The Australian
Dimerix和Amicus Therapeutics在美国商业化肾脏疾病治疗DMX-200的合作伙伴 - 澳洲财经新闻 | 澳洲财经见闻 ...
| Bioshares
Key paediatric milestone reached in Dimerix’s kidney-disease drug trial ...
Three reasons why we like $DXB (Dimerix Limited) - Uninformed Investors
Key findings could boost Dimerix’s rare kidney disease drug trial ...
.png&w=3840&q=75)
